Endothelin-converting enzyme inhibitor
US11278748B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 31, 2017 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Oct 31, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provision of a material, which has activity of inhibiting endothelin-converting enzyme and is effective for skin whitening or antihypertension. An endothelin-converting enzyme inhibitor comprising, as an active ingredient, at least one selected from the group consisting of Hiptage candicans, Piper sarmentosum, Solanum stramonifolium, Anaxagorea luzonensis, Smilax corbularia, Ardisia elliptica, Erythrina suberosa, Dactyloctenium aegyptium, Hopea ferrea and extracts thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.